C WorldWide Group Holding A S increased its position in shares of Puma Biotechnology Inc (NYSE:PBYI) by 19.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,834 shares of the biopharmaceutical company’s stock after buying an additional 6,465 shares during the period. C WorldWide Group Holding A S owned about 0.11% of Puma Biotechnology worth $3,481,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Camber Capital Management LLC bought a new position in shares of Puma Biotechnology during the first quarter worth about $24,180,000. Redmile Group LLC increased its position in shares of Puma Biotechnology by 33.7% in the first quarter. Redmile Group LLC now owns 1,725,414 shares of the biopharmaceutical company’s stock worth $64,185,000 after buying an additional 435,274 shares during the last quarter. Emerald Advisers Inc. PA bought a new position in shares of Puma Biotechnology during the first quarter worth about $14,110,000. Emerald Mutual Fund Advisers Trust bought a new position in shares of Puma Biotechnology during the first quarter worth about $9,702,000. Finally, Norges Bank bought a new position in shares of Puma Biotechnology during the fourth quarter worth about $7,693,000. 80.98% of the stock is currently owned by institutional investors and hedge funds.
Shares of Puma Biotechnology Inc (NYSE PBYI) opened at 78.45 on Friday. Puma Biotechnology Inc has a 52-week low of $28.35 and a 52-week high of $98.85. The stock’s market capitalization is $2.90 billion. The stock has a 50 day moving average of $88.59 and a 200-day moving average of $56.34.
Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing the consensus estimate of ($1.32) by $0.78. Analysts predict that Puma Biotechnology Inc will post ($8.63) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology Inc (NYSE:PBYI) Shares Bought by C WorldWide Group Holding A S” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://stocknewstimes.com/2017/08/12/puma-biotechnology-inc-nysepbyi-shares-bought-by-c-worldwide-group-holding-a-s.html.
A number of research analysts have issued reports on PBYI shares. Stifel Nicolaus reissued a “buy” rating and set a $88.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, April 19th. Zacks Investment Research raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research report on Tuesday, May 16th. Credit Suisse Group reissued an “outperform” rating and set a $58.00 price objective on shares of Puma Biotechnology in a research report on Tuesday, April 18th. J P Morgan Chase & Co reissued an “overweight” rating and set a $89.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, May 24th. Finally, Leerink Swann reissued an “outperform” rating and set a $125.00 price objective (up from $115.00) on shares of Puma Biotechnology in a research report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $109.56.
In related news, SVP Richard Paul Bryce sold 1,998 shares of Puma Biotechnology stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the completion of the sale, the senior vice president now directly owns 27,246 shares in the company, valued at $2,574,202.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of Puma Biotechnology stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $75.38, for a total value of $93,147,066.00. The disclosure for this sale can be found here. Insiders sold 2,010,261 shares of company stock valued at $159,425,452 over the last 90 days. 22.70% of the stock is currently owned by corporate insiders.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.